Global Left Atrial Appendage Closure Devices Market is anticipated to rise at a value CAGR of 25% over 2019-2028. According to a study published by Insure Insights on the Global Left Atrial Appendage Closure Devices Market. Left atrial appendage closure is also known as Left atrial appendage occlusion, is a treatment strategy used to reduce the risk of left atrial appendage blood clots from entering the bloodstream and thus causing a stroke in patients with non-valvular atrial fibrillation. The lifestyle habits like smoking and alcohol consumption, the growth in the geriatric population have triggered the market growth.

Top Driver: The rise in the incidences of atrial fibrillation have driven the market

The increasing prevalence of cardiovascular diseases, increasing occurrence of atrial fibrillation across the globe are the primary factors contributing to market growth. The rise in the government initiatives to generate awareness about cardiac disorders and the presence of technologically developed products are the significant factors boosting the market demand for left atrial appendage closure devices over the forecast period.

Epicardial LAA closure devices have held the highest segmental growth in the Global Left Atrial Appendage Closure Devices Market

Based on the product Epicardial LAA closure devices segment have poised the most lucrative growth as they do not require the implanting a permanent device and d also do not need an anticoagulation post-procedure. Owing to these factors Epicardial LAA closure devices are expected to have the highest growth in the forecast period

In terms of the procedure, Surgical segment has held the most remarkable growth in the market due to the availability of various surgical processes to LAA occlusion like stapler excision, epicardial exclusion clips, suture exclusion, and also assist preventing clot formation at the time of LAA occlusion. In terms of the End-user, Hospitals segment have held the most significant growth due to the availability of trained physicians and advanced healthcare infrastructure.

The technological advances in North America prove Lucrative to the market  

The highly developed technology in healthcare, advances in the field of biotechnology, rise in the research activities have positively impacted the regional market of North America. The advanced healthcare infrastructure, favorable reimbursement, and availability of skilled personnel have improved the overall market. The popularity of medical tourism and the rise in the incidences of cardiac disorders have escalated the regional revenue of North America. Asia Pacific is expected to grow at a high CAGR owing to the rise in government initiative for healthcare activities, availability of technological advances equipment at a cheaper rate, have fostered the region, etc.

Technological advancements, Product launches, Mergers, and Acquisition, are the major strategies of the competitors

The Players of the Global Left Atrial Appendage Closure Devices Market is fragmented.  Technological advances, Product launches, Mergers, and Acquisition, are strategies used by the competitors   The key competitors of the Global Left Atrial Appendage Closure Devices Market Conformal Medical, Sentreheart, Inc., Dune Medical Devices, Coherex Medical, Lifetech Scientific (Shenzhen), Abbott, Atricure, Johnson and Johnson and Boston Scientific Corporation.

Conformal Medical:  Conformal Medical is one of the key competitors of the Global Left Atrial Appendage Closure Devices Market; for instance, In January 2020, Conformal Medical, had announced their first left atrial appendage closure for LAAC cases, it is equipped with unique CLAAS Technology, it is designed for patients under conscious sedation without general anesthesia. The CLAAS technology assists in simpler delivery for the patients in sedation.

Boston Scientific Corporation. Boston Scientific Corporation is a popular competitor in the Global Left Atrial Appendage Closure Devices Market. In August 2019, Boston Scientific Corporation had announced the acquisition of BTG; they manufacture interventional oncology therapeutics for patients with liver and kidney cancers and are involved in producing non-invasive devices. The deal was done for USD 4.2 billion. The acquisition was made by Boston Scientific Corporation to strengthen its product portfolio.

Scope of the Report

By Product

• Endocardial LAA closure devices
• Epicardial LAA closure devices

By Procedure

• Surgical
• Percutaneous

By End User

• Hospitals
• Ambulatory Surgery Centres
• Others

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.